Current and historical daily PE Ratio for Hangzhou Tigermed Consulting Co Ltd (
SZSE:300347
) from 2012 to Jun 06 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Hangzhou Tigermednsulting Co stock (SZSE:300347) PE ratio as of Jun 06 2024 is 28.92.
More Details
Hangzhou Tigermed Consulting Co Ltd (SZSE:300347) PE Ratio (TTM) Chart
Hangzhou Tigermed Consulting Co Ltd (SZSE:300347) PE Ratio (TTM) Historical Data
View and export this data going back to 2012. Start your Free Trial
Total 1199
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Hangzhou Tigermednsulting Co PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-06-06 | 29.2 | 2024-03-28 | 26.8 |
| 2024-06-05 | 28.4 | 2024-03-27 | 21.8 |
| 2024-06-04 | 28.5 | 2024-03-26 | 21.4 |
| 2024-06-03 | 27.5 | 2024-03-25 | 21.3 |
| 2024-05-31 | 27.7 | 2024-03-22 | 20.5 |
| 2024-05-30 | 27.6 | 2024-03-21 | 21.5 |
| 2024-05-29 | 27.3 | 2024-03-20 | 21.9 |
| 2024-05-28 | 28.1 | 2024-03-19 | 22.4 |
| 2024-05-27 | 28.4 | 2024-03-18 | 22.6 |
| 2024-05-24 | 28.2 | 2024-03-15 | 22.3 |
| 2024-05-23 | 28.3 | 2024-03-14 | 22.3 |
| 2024-05-22 | 29.2 | 2024-03-13 | 18.6 |
| 2024-05-21 | 29.8 | 2024-03-12 | 18.9 |
| 2024-05-20 | 29.9 | 2024-03-11 | 18.4 |
| 2024-05-17 | 29.2 | 2024-03-08 | 17.7 |
| 2024-05-16 | 29.8 | 2024-03-07 | 17.6 |
| 2024-05-15 | 29.2 | 2024-03-06 | 18.9 |
| 2024-05-14 | 30.4 | 2024-03-05 | 19.1 |
| 2024-05-13 | 29.6 | 2024-03-04 | 20.0 |
| 2024-05-10 | 30.6 | 2024-03-01 | 19.3 |
| 2024-05-09 | 30.6 | 2024-02-29 | 19.3 |
| 2024-05-08 | 30.7 | 2024-02-28 | 18.6 |
| 2024-05-07 | 31.6 | 2024-02-27 | 19.1 |
| 2024-05-06 | 31.7 | 2024-02-26 | 18.9 |
| 2024-04-30 | 30.3 | 2024-02-23 | 18.7 |
| 2024-04-29 | 30.6 | 2024-02-22 | 18.8 |
| 2024-04-26 | 29.6 | 2024-02-21 | 18.8 |
| 2024-04-25 | 27.2 | 2024-02-20 | 18.5 |
| 2024-04-24 | 27.0 | 2024-02-19 | 18.2 |
| 2024-04-23 | 27.2 | 2024-02-08 | 18.3 |
| 2024-04-22 | 25.5 | 2024-02-07 | 18.2 |
| 2024-04-19 | 25.5 | 2024-02-06 | 17.4 |
| 2024-04-18 | 26.5 | 2024-02-05 | 16.2 |
| 2024-04-17 | 27.1 | 2024-02-02 | 16.5 |
| 2024-04-16 | 27.2 | 2024-02-01 | 17.5 |
| 2024-04-15 | 28.9 | 2024-01-31 | 17.4 |
| 2024-04-12 | 28.6 | 2024-01-30 | 18.4 |
| 2024-04-11 | 28.8 | 2024-01-29 | 18.5 |
| 2024-04-10 | 29.6 | 2024-01-26 | 18.8 |
| 2024-04-09 | 29.2 | 2024-01-25 | 20.9 |
| 2024-04-08 | 27.0 | 2024-01-24 | 20.4 |
| 2024-04-03 | 25.8 | 2024-01-23 | 20.4 |
| 2024-04-02 | 26.7 | 2024-01-22 | 20.1 |
| 2024-04-01 | 27.2 | 2024-01-19 | 20.9 |
| 2024-03-29 | 27.3 | 2024-01-18 | 21.4 |
Hangzhou Tigermed Consulting Co Ltd (SZSE:300347) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Hangzhou Tigermed Consulting Co Ltd
NAICS : 541711
SIC : 8731
ISIN : CNE100001KV8
Share Class Description:
SZSE:300347: Class ACompare
Compare
Traded in other countries / regions
300347.China03347.Hong Kong5HZ1.GermanyHNGZY.USA IPO Date
2012-08-17Description
Hangzhou Tigermed Consulting Co Ltd is a China-based Contract Research Organization. The company's segment includes Clinical trial solutions and Clinical-related and laboratory services. It generates maximum revenue from the Clinical trial solutions segment. The company's offered services include bioanalytical, medical writing, biostatistics analysis, and medical imaging. The therapeutic areas of the company include Infections, Hematology, Cardiovascular, Endocrinology, Rheumatology, Nephrology, and Central Nervous System (CNS) among others.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers